US › Healthcare

Cibus Global LLC (CBUS)

US · Healthcare · Biotechnology

$1.32+2.33%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$994,000

Revenue YoY

+6.5%

Net profit

$-22.1M

EPS

$-0.29

EPS estimate

$-0.26

Net margin

-2,227.9%

EPS came in at -0.29 against a street estimate of -0.26 — a miss of 11.5%.

Key statistics

Market cap

$113.1M

Forward P/E

0.0

P/B

7.95

Book value

$0.19

EPS (TTM)

$-1.62

52-week high

$4.19

52-week low

$1.09

50-day MA

$1.66

200-day MA

$1.89

Beta

1.57

Analyst view

Analysts rate Cibus Global LLC a buy (2 buy, 1 hold, 0 sell out of 3) with an average price target of $14.33.

Shareholding

Insiders

26.10%

Institutions

29.18%

Largest institutional holders

Fund	Stake
FMR Inc	14.98%
Vanguard Capital Management, LLC	3.01%
United Capital Financial Advisers Inc	0.75%
Geode Capital Management, LLC	0.69%
BlackRock Inc	0.64%
Prescott Group Capital Management LLC	0.43%
Squarepoint Ops LLC	0.41%
Vanguard Fiduciary Trust Co	0.41%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cibus Global LLC — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.